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ess: papiris@otenet.grSummary Background: Medical Research Council (MRC) chronic dyspnea scale,
used for the estimation of disability due to dyspnea, may serve as a simple index of
disease severity and extent in patients with idiopathic pulmonary fibrosis (IPF).
However, its relationship with other commonly used measures has not been
evaluated.
Methods: The association of MRC chronic dyspnea scale with lung function indices
and high-resolution computerized tomography (HRCT) scores such as the total
interstitial disease score (TIDs) and the fibrosis score (Fs) was examined in 26
untreated patients with IPF sequentially recruited over a period of 3 years. The aim
of this observational study was to explore the relationship between dyspnea,
impairment of lung function and CT estimation of disease severity in patients with
IPF.
Results: The MRC dyspnea score was significantly associated with FVC, FEV1, TLC,
DLCO, PaO2, and PaCO2 and with both HRCT scores. In multiple regression analysis
only the FVC (OR ¼ 0:85; 95% CI ¼ 0:7520:95; P ¼ 0:004) and PaCO2 (OR ¼ 0:69; 95%
CI ¼ 0:5020:95; P ¼ 0:02) correlated with dyspnea. Furthermore, both TIDs and Fs
were negatively associated with FVC, FEV1, TLC and PaO2. In multiple regression
analysis only the FVC correlated with both TIDs (r2 ¼ 0:57; P ¼ 0:0001) and Fs
(r2 ¼ 0:46; P ¼ 0:0005).
Conclusions: These observations suggest that the MRC dyspnea scale could offer
useful information about the estimation of severity in patients with IPF. FurthermoreElsevier Ltd. All rights reserved.
e Department, 45-47 Ipsilantou street, ‘‘Evangelismos’’ Hospital, GR 10675, Athens, Greece,
470.
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& 2004 Elsevier Ltd. All rights reserved.Introduction
Exertional dyspnea is the most prominent and
disabling symptom in patients with idiopathic
pulmonary fibrosis (IPF).1,2 Estimation of dyspnea
by the Medical Research Council (MRC) chronic
dyspnea scale is simple to administer and has been
used for many years for grading the effects of
breathlessness on daily activities.3 This scale has
been particularly used in patients with chronic
obstructive pulmonary disease (COPD) in whom it
has proved to be useful and complementary to FEV1
in the classification of disease severity.4 However,
the relationship of (MRC) chronic dyspnea scale to
other commonly used measures has not been
evaluated in IPF patients.
Lung function parameters provide useful infor-
mation in the assessment of status and progress in
IPF.5 High-resolution computerized tomography
(HRCT) is a sensitive means for diagnosing IPF,6,7
and also has been increasingly used for quantifica-
tion of the disease severity. To the best of our
knowledge, there are no studies in which the
simple and self-administered MRC chronic dyspnea
scale has been associated with lung function
parameters, radiological estimates of disease se-
verity and extent (HRCT scores) in IPF.
The aim of the current study was to explore the
association between MRC chronic dyspnea scale,
lung function indices and HRCT scores in IPF
patients. In addition, we studied the association
between HRCT scores and lung function indices.Methods
Subjects
The population studied consisted of 26 untreated
patients (15 males, aged 41–80 yr), with clinical
and radiological features of IPF. They were
recruited sequentially from the respiratory out-
patient clinic over a period of 3 years. All patients
fulfilled the criteria for the diagnosis of IPF
established by the American Thoracic Society, the
European Respiratory Society, and the American
College of Chest Physicians.1 Histological features
of usual interstitial pneumonia (UIP) were con-
firmed by video-assisted thoracoscopic biopsy in 22
patients. Fourteen patients were never smokers, 3current smokers and 9 ex-smokers. The study was
approved by the institutional ethics committee and
informed consent was obtained from each patient.
Pulmonary function tests
The lung function tests included FEV1, FVC, FEV1/
FVC ratio, total lung capacity (TLC), residual
volume (RV) and DLCO. TLC and RV were measured
by the helium dilution method with a Master Screen
apparatus (Erich Jaeger GmbH, Wuerzburg, Ger-
many), and DLCO by the single breathholding
helium dilution method.8,9 Measurements were
expressed as percentages of predicted values.8,9
In all patients, the arterial PaO2 and PaCO2 were
also measured at rest.
Dyspnea
Dyspnea was assessed by the modified MRC chronic
dyspnea self-administered questionnaire that con-
sists of six questions about perceived breathless-
ness: 3,11 category 0, no dyspnea; category 1, slight
degree of dyspnea (troubled by shortness of breath
when hurrying on the level or walking up a slight
hill); category 2, moderate degree of dyspnea
(walks slower than people of the same age on the
level because of breathlessness); category 3,
moderately severe degree of dyspnea (has to stop
because of breathlessness when walking at own
pace on the level); category 4, severe degree of
dyspnea (stops for breath after walking about 100
yards or after a few minutes on the level); category
5, very severe degree of dyspnea (too breathless to
leave the house or breathless when dressing or
undressing).
HRCT
The HRCT examination was performed within a 1-
month interval from the pulmonary function tests
and lung biopsy. The CTscans were performed using
either a Somaton HiQ or a Somaton Plus scanner
(Siemens, Erlanger, Germany). All patients under-
went conventional computed tomography scanning
of the chest, using a 10-mm section thickness at 10-
mm intervals. The HRCT scans were obtained at six
predetermined levels: large vessels, aortic arch,
tracheal carina, pulmonary hilum, pulmonary ve-
nous confluence, and 1 cm above the right dia-
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section thickness and a 1–2 s scanning time during
breath holding at end inspiration. These scans were
reconstructed with a high spatial frequency algo-
rithm and viewed at window levels appropriate for
pulmonary parenchyma (level 500 to 700 Houns-
field units: width 1000–1600 Hounsfield units).
CT scoring: Two independent experienced read-
ers (SP, KM), without any knowledge of the clinical
and functional findings, examined the HRCT scans.
The HRCTscoring included the extent of: (a) ground
glass opacities without evidence of bronchiolectasis
and bronchiectasis, the pure ground glass score
(PGGs); (b) ground glass opacities with coexisting
bronchiolectasis and bronchiectasis, the ground
glass score (GGs); (c) fine reticulation; and (d)
coarse reticulation. Finally, the composite extent
scores calculated were the fibrosis score (Fs),
composed by the sum of fine and coarse reticula-
tion and the total interstitial disease score (TIDs)
composed by the sum of all the above-mentioned
scores (PGGs+GGs+Fs). Extent of involvement was
assessed by the HRCT slices using a visual method,
similar to that used previously by other investiga-
tors, 7,10–13 recording the relative proportion of all
the above findings to within 5%. Scores from the six
HRCT slices were summed and divided by the total
number of slices to calculate the average extent
score for each of the variables. Similar methods of
scoring have been used by Staples and coworkers,10
Lee and coworkers,11 and Wells and co-workers.7,12
Evaluations of HRCT and scoring were done sepa-
rately and mean values from the two readers were
included for correlations.Table 1 Radiographic and lung function data at
presentation.
Patients (n ¼ 26)
PGGs (%) 0* (0–18)*
Fs (%) 2873
TIDs (%) 3373
FEV1 (% pred) 7973
FVC (% pred) 7973
FEV1/FVC (ratio) 8671
TLC (% pred) 6673
DLCO (% pred) 4973
PaO2 (mmHg) 7374
PaCO2 (mmHg) 3771
PGGs= pure ground glass score; Fs=fibrosis score; TID-
s=total interstitial disease score.Data are presented as
means7SEM.
*Median and range.Statistical analysis
Results are presented as mean7SEM. In a univariate
analysis, the relationships were examined through
correlation analysis. For the MRC dyspnea score,
since it is an ordinal categorical variable, the
Spearman rank correlation coefficient was calcu-
lated, as it is more appropriate for such type of
data. For the HRCT scores Pearson correlation
coefficient was utilized for normally distributed
data while the Spearman rank correlation coeffi-
cient was otherwise used. If both examined vari-
ables were normally distributed then the Pearson
correlation coefficient was used to describe the
relationship, otherwise the rank correlation coeffi-
cient was used. Differences between smokers and
never smokers were also examined in all above-
mentioned variables using the t-test for indepen-
dent samples, where appropriate, or by the
Wilcoxon Ranks Sum test. Variables significantlycorrelated with HRCT and MRC scores were further
used as explanatory variables in a multivariate
analysis. For the HRCT scores a backward stepwise
multiple linear regression analysis was performed.
A natural logarithmic transformation in TID score
and disease duration was made a priori to achieve
normality. For MRC score, which is an ordinal
categorical variable, generalized linear models
were fitted and the best was selected through
multiple stepwise logistic regression analysis for
ordinal response.14 A P-valueo0.05 was considered
statistically significant. Analysis was performed
using the SAS System software.
Interobserver variability in grading HRCT extent
of involvement was quantified using the paired t-
test and kappa value for the nearest to 5% reading.
Kappa coefficient expresses the agreement be-
tween observers after removal of the component of
agreement attributable to chance.Results
Twenty-six patients (15 males, aged 41–80 yr) were
studied. All patients claimed some degree of
dyspnea (MRC score40) and all were ambulatory
(nobody with MRC score of 5). There were 7
patients with MRC grade 1 dyspnea, 11 patients
with MRC grade 2 dyspnea, 6 patients with MRC
grade 3 dyspnea and 2 patients with MRC grade 4
dyspnea. HRCT scores and lung function data are
shown in Table 1. No emphysema was evident in the
HRCTs. Most patients had a restrictive lung function
pattern characterized by a decrease in TLC (80% of
patients) and FEV1/FVC ratio X 75% (100% of
patients). The DLCO was decreased in 92% of them.
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smokers and never-smokers in HRCT, MRC dyspnea
scores and lung function data. There were no
significant differences between the two observers
in the estimation of HRCT scores for the TID and F
scores. Kappa values indicated good agreement
between the two observers for the Fs (0.50), and
the TIDs (0.66).Figure 1 Relationship between MRC dyspnea score and
FVC (Rank correlation coefficient rs ¼ 0:75; P ¼ 0:0001)
(A) and PaCO2 (Rank correlation coefficient rs ¼ 0:47;
P ¼ 0:01) (B). Each solid circle represents results from
one subject.Correlation between MRC dyspnea score,
lung function parameters and HRCT scores
The MRC dyspnea score was negatively correlated
with all lung function parameters studied except RV
and FEV1/FVC ratio (Table 2).
Among the HRCTscores studied, the MRC dyspnea
score was positively correlated with both TIDs
(rS ¼ 0:60; P ¼ 0:003) and Fs (rS ¼ 0:49; P ¼ 0:02).
However, in multiple stepwise regression analysis
with MRC dyspnea score as the dependent variable
and lung function parameters and HRCT scores as
the independent variables FVC (Odds ratio=0.85,
95% CI: 0.75–0.95, P ¼ 0:004) and PaCO2 (Odds
Ratio=0.69, 95% CI: 0.50–0.95, P ¼ 0:02) were
selected as the only parameters that significantly
(negatively) correlated with the dyspnea grade
(Figs. 1A and B).Correlation between HRCT scores and lung
function parameters
No significant correlation was found between the
PGG score and any lung function indices studied.
However, both TIDs and Fs were negatively corre-
lated with FVC, FEV1, TLC and PaO2 (Table 3).
According to multiple stepwise regression analysis,
among these four lung function indices, only FVC
correlated significantly with both the Fs (r2 ¼ 0:46;
P ¼ 0:0005) and the TIDs (r2 ¼ 0:57; P ¼ 0:0001).Table 2 Significant Spearman’s correlation coef-
ficients (rS) of MRC dyspnea scale to lung function
data.
Lung function data rS P-value
FVC (% pred) 0.75 0.0001
PaO2 (mmHg) 0.73 0.0001
FEV1 (% pred) 0.64 0.0004
TLC (% pred) 0.62 0.0007
DLCO (% pred) 0.56 0.005
PaCO2 (mmHg) 0.47 0.01Discussion
The purpose of this study was to determine the
level of association between disability due to
breathlessness categorized by the MRC dyspnea
scale and other variables used to evaluate the
disease severity and extent in patients with IPF. The
first finding was that the MRC dyspnea score was
significantly associated with FVC, PaO2, FEV1, TLC,
DLCO and PaCO2 and with TIDs and Fs, indices that
reflect the global radiological extent and fibrosis
stage of IPF, respectively. Even though all patients
with IPF demonstrate a progressive worsening of
dyspnea that affects their overall health status,1
few studies have correlated the MRC chronic
dyspnea scale to physiological and radiological
estimates of disease severity and extent. In the
study by Martinez and co-workers15 it was found
that chronic dyspnea, assessed as the baseline
dyspnea index (BDI) is far better contributor to the
quality of life in these patients than the lung
function variables studied (FEV1 and FVC). In this
study the clinical rating used to quantify chronic
dyspnea differed from the MRC dyspnea scale.
However, Mahler and Wells have shown that the
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Table 3 Significant Spearman’s correlation coefficients (rS) of HRCT scores to lung function data (n ¼ 22)
Lung function data TIDs Fs
rS P-value rS P-value
FVC (% pred) 0.69 0.0004 0.68* 0.0005
FEV1 (% pred) 0.59 0.004 0.53 0.01
TLC (% pred) 0.76 0.0001 0.64* 0.001
PaO2 (mmHg) 0.59 0.004 0.64* 0.002
*Pearson correlation coefficient.
Dyspnea in idiopathic pulmonary fibrosis 759BDI, and MRC chronic dyspnea scale were highly
correlated.16
The correlation between HRCT scores and dys-
pnea score found in this study is in agreement with
Hartley and co-workers.17 They reported a good
correlation between a complex computer-derived
index of lung parenchyma density based on the
HRCT scan and both the FVC and the level of
dyspnea in patients with IPF. Our findings are also in
agreement with those reported by Staples and co-
workers10 and Terriff and co-workers18 who found a
correlation between HRCT scores and severity of
dyspnea, though their dyspnea scales were differ-
ent from the MRC chronic dyspnea scale used in the
present study.
The second finding was that both TIDs and Fs
were significantly associated with FVC, FEV1, TLC
and PaO2. In the studies of Staples and Terriff
mentioned above TLC and DLCO but not FVC
correlated with the HRCT scores.10,18 However,
Terriff and co-workers evaluated only the signifi-
cance of ground glass or reticulation, but not the
global extent of the disease in HRCT. In more recent
studies,5,19–21 based on global HRCT estimates of
disease severity and extent, it has been shown that
this morphological parameter correlates well with
indices of functional lung impairment and chronic
dyspnea in only one of them, though a very
different dyspnea scale has been used in that
study.20 In the study of Xaubet and co-workers the
FVC was found to be a significant and independent
correlate of HRCT abnormalities as in the present
study. However, they also found that the DLCO was
significantly correlated with the severity of the
disease.5 Furthermore, in the study by Wells and
co-workers20 it has been shown that the global
extent of IPF, assessed in terms of HRCT, best
correlated with DLCO (r ¼ 0:68), though the
correlation with FVC (r ¼ 0:37) was also signifi-
cant. In the study of Brantly and coworkers21 FVC
and DLCO correlated equally well (r ¼ 0:66 for
both). The above discrepancies among previous
studies and the present results are difficult toexplain but may be related to the variable course of
the disease, to the fact that somewhat different
methodologies have been used5,7,10,18,19,21 and also
to the fact that some previous works included
patients with interstitial lung disease associated
with conditions such as connective tissue disor-
ders.7,10,24
Finally, according to the multiple stepwise
regression analysis, only FVC was selected as
significant predictor in virtually all relationships
studied. This is not surprising given the fact that
the extent of pulmonary fibrosis with concurrent
increase in pulmonary elastance is necessarily
reflected by decreased FVC and concurrent in-
crease in work of breathing leading to dyspnea.22
Furthermore, the HRCT indices of global lung
disease used in this study correlate well with FVC,
which decreases progressively with disease dura-
tion. The importance of FVC in IPF could be higher
if a good predictive ability for survival could be
demonstrated. In this regard, however, controversy
still exists. While some studies have confirmed that
baseline FVC offers independent predictive ability
in determining the risk of death,23–25 others26,27
have not. Probably the main reason of this
controversy relates to the fact that the cause of
death in IPF is multifactorial since mortality is due
to respiratory failure only in the 39% of patients,
the majority as a single cause but still a minority
overall.28 Recent studies have shown that changes
in clinical and physiological variables and among
them changes in dyspnea score and FVC, over 6 and
12 months may offer more accurate prognostic
information.29,30
The fact that PaCO2 was selected as the second
significant predictor of dyspnea indicates that the
more the patients hyperventilate the more dyspnea
they have, which is in line with the fact that
virtually every patient with IPF will develop
dyspnea, first on exertion and next at rest, as
the disease progresses. Indeed, Rampulla and
coworkers found that the most frequent
symptom limiting exercise capacity in interstitial
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that although patients with restrictive pulmonary
disease often hyperventilate, this phenomenon is
most common in patients with interstitial lung
disease.32 This suggests some role to lung parench-
ymal fibro-inflammatory milieu in the generation of
stimuli from the lung parenchyma.
In conclusion, the close correlation observed in
the present study between the MRC dyspnea score
and some of the most representative functional and
radiological indices of disease severity and extent,
indicates that the estimation of dyspnea with a
simple and self-administered questionnaire is a
useful adjunct in the assessment of the clinical
status of patients with IPF. However, because of the
relatively small size of the population studied,
further studies are needed to support our findings.
In addition, it would be useful to validate the
predictive value of MRC dyspnea score in the
disease progression and survival.Acknowledgments
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